NRAS and KRAS polymorphisms are not associated with hepatoblastoma susceptibility in Chinese children

Table 3 Association between KRAS genotypes and hepatoblastoma susceptibility after stratification by age, gender, and clinical stages

Variables	rs12587 (patients/controls)		AOR (95% CI)^a	P ^a	rs7973450 (patients/controls)		AOR (95% CI)^a	P ^a	rs7312175 (patients/controls)		AOR (95% CI)^a	P ^a	Combined genotypes (patients/controls)		AOR (95% CI)^a	P ^a
Variables	GG	GT/TT	AOR (95% CI)^a	P ^a	AA	AG/GG	AOR (95% CI)^a	P ^a	GG	GA/AA	AOR (95% CI)^a	P ^a	0	1–3	AOR (95% CI)^a	P ^a
Age, months
< 17	70/278	44/176	1.00 (0.66–1.53)	0.998	90/371	24/83	1.20 (0.72–2.00)	0.486	94/358	20/106	0.70 (0.41–1.19)	0.189	73/275	41/179	0.87 (0.57–1.33)	0.517
≥ 17	58/331	41/173	1.35 (0.87–2.10)	0.179	88/427	11/77	0.69 (0.35–1.36)	0.286	73/392	26/112	1.25 (0.76–2.04)	0.383	66/330	33/174	0.95 (0.60–1.50)	0.817
Gender
Female	49/222	35/157	0.99 (0.61–1.60)	0.963	68/311	16/68	1.03 (0.56–1.90)	0.916	67/284	17/95	0.76 (0.42–1.35)	0.344	54/223	30/156	0.77 (0.47–1.26)	0.302
Male	79/387	50/192	1.27 (0.86–1.89)	0.231	110/487	19/92	0.92 (0.54–1.57)	0.750	100/456	29/123	1.07 (0.68–1.70)	0.765	85/382	44/197	1.01 (0.67–1.50)	0.980
Clinical stages
I + II	56/609	41/349	1.28 (0.84–1.97)	0.249	75/798	22/160	1.47 (0.89–2.44)	0.132	76/740	21/218	0.94 (0.57–1.56)	0.803	60/605	37/353	1.06 (0.69–1.64)	0.784
III + IV	32/609	23/349	1.25 (0.72–2.17)	0.430	48/798	7/160	0.73 (0.32–1.64)	0.445	44/740	11/218	0.85 (0.43–1.67)	0.626	37/605	18/353	0.83 (0.47–1.48)	0.532

ISSN: 2162-3619